PolyPeptide Group AI Market Strategy Report - Peptide API Manufacturing

Answer Capsule

PolyPeptide Group holds a visible but under-recommended position in AI-generated recommendations for Peptide API Manufacturing. In September 2026, the brand appeared in 26.07% of qualified AI observations but received valid recommendation coverage of only 5.84%, a gap of more than 20 percentage points between presence and recommendation. Its top-three recommendation rate fell from 7.60% in July 2026 to 1.95% in September 2026, and it holds no rank-one recommendations. The clearest opportunity is converting its rising presence into shortlist placement, particularly in the Brand Recommendation cluster where all qualified observations currently sit.

Who This Report Is For

This report is for PolyPeptide Group's commercial leadership, market access, and business development teams, and for category buyers evaluating how peptide API manufacturers are positioned in AI-led supplier discovery.

Report Card

Executive Summary

PolyPeptide Group is visible in AI-generated recommendations for Peptide API Manufacturing but is not being chosen at the rate its presence would suggest. The brand appeared in 67 of 257 qualified observations in September 2026, a raw mention presence rate of 26.07%, yet it received valid recommendation coverage of only 5.84%. That gap between being mentioned and being recommended is the defining feature of its current position.

The benchmark shows PolyPeptide Group delivered 15 valid recommendations in September 2026, down from 22 in July 2026. Its top-three recommendation count fell from 17 to 5 over the same period, and its top-three rate declined 5.6 percentage points from 7.60% to 1.95%. The brand holds no rank-one recommendations in the September dataset. Its average recommended rank of 3.4 indicates that when it does receive rank credit, it typically appears in the middle of the recommendation set rather than at the top.

The strongest signal for PolyPeptide Group is its sentiment profile. With 62 positive mentions, 5 neutral mentions, and zero negative mentions, its net sentiment score of 0.9254 is the second highest among tracked brands. AI systems are not framing the brand negatively. The issue is not reputation but recommendation conversion.

The weakest cluster is the only qualified cluster. All 257 qualified observations in September 2026 fell into the Brand Recommendation class of discovery. The Pricing and Value and Multi-Brand Comparison clusters contained zero qualified observations. This means the benchmark cannot yet show how PolyPeptide Group performs when buyers ask about cost, value, or head-to-head supplier trade-offs.

The strongest platform signal for PolyPeptide Group is Google AI Mode, where the brand delivered 3 valid recommendations from 11 present observations, a valid recommendation coverage of 4.62% on that platform. Google AI Overviews also showed recommendation activity, with 1 valid recommendation from 20 present observations. The brand has no presence on Copilot or ChatGPT in the September dataset, and its Gemini presence of 19 observations converted to zero top-three recommendations.

The clearest platform gap is Copilot, where PolyPeptide Group appeared in 6 observations but received only 1 top-three recommendation and no rank-one placements. The brand's presence on that platform is not translating into shortlist positioning. The broader pattern across platforms is consistent: PolyPeptide Group is being mentioned as context, not recommended as a supplier.

What PolyPeptide Group Is Winning

Questions This Section Answers

• Where does PolyPeptide Group actually outperform competitors in AI responses?
• How strong is PolyPeptide Group's sentiment profile compared with other peptide API manufacturers?

PolyPeptide Group's clearest win is its sentiment profile. With 62 positive mentions, 5 neutral mentions, and zero negative mentions across 67 present observations, the brand's net sentiment score of 0.9254 is the second highest in the tracked set, behind only Biosynth Peptide Division at 1.00. AI systems are not associating the brand with cautionary or negative framing.

The brand also holds a meaningful presence advantage over several competitors. Its raw mention presence rate of 26.07% is the third highest in the category, behind Bachem at 92.61% and AmbioPharm at 39.30%. PolyPeptide Group appears in more AI responses than Biosynth Peptide Division, CPC Scientific, CordenPharma Peptides, and CSBio.

On Google AI Mode, PolyPeptide Group delivered 3 valid recommendations and 3 top-three placements from 11 present observations, a top-three rate of 4.62% on that platform. This is the brand's strongest platform-level recommendation signal. Google AI Overviews also produced 1 valid recommendation from 20 present observations.

These wins are real but narrow. The brand has positive framing and moderate presence. It does not have recommendation power at scale.

Where PolyPeptide Group Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why is PolyPeptide Group mentioned in AI responses but not recommended as a supplier?
• How does PolyPeptide Group's recommendation conversion compare with Bachem and AmbioPharm?
• On which AI platforms does PolyPeptide Group's presence fail to translate into shortlist placement?

PolyPeptide Group's primary gap is recommendation conversion. The brand appeared in 67 qualified observations in September 2026 but received valid recommendation coverage in only 15 of them. Its top-three rate of 1.95% means it appears in the first three recommended positions in fewer than 2 in 100 qualified observations. Its rank-one rate is 0.00%, meaning it is never the first recommendation in the September dataset.

The gap between presence and recommendation is widening. In July 2026, PolyPeptide Group had a raw mention presence rate of 21.8% and a valid recommendation coverage of 9.8%. By September 2026, presence had risen to 26.07% while recommendation coverage had fallen to 5.84%. The brand is appearing in more AI responses but being recommended in fewer of them. This pattern suggests its mentions have shifted toward contextual or informational roles rather than supplier recommendations.

The competitive contrast is stark. Bachem, the category leader, holds a top-three rate of 25.29% and a rank-one rate of 14.79%. PolyPeptide Group's top-three rate is 1.95% and its rank-one rate is 0.00%. Even AmbioPharm, which declined significantly from July to September, holds a top-three rate of 5.06% and a rank-one rate of 1.17%, both higher than PolyPeptide Group.

The platform-level gaps reinforce the pattern. On Copilot, PolyPeptide Group appeared in 6 observations but received only 1 top-three recommendation. On Gemini, the brand appeared in 19 observations but received zero top-three recommendations. On ChatGPT, it appeared in 6 observations with 1 valid recommendation but no top-three placement. The brand is present across platforms but is not being shortlisted.

The cluster-level gap is equally clear. All qualified observations in September 2026 fell into the Brand Recommendation cluster. PolyPeptide Group's valid recommendation coverage within that cluster is 5.84%. The benchmark does not yet contain qualified observations in the Pricing and Value or Multi-Brand Comparison clusters, so the brand's performance in those buyer-intent contexts is not measured.

Biggest Opportunity

Questions This Section Answers

• What would it take for PolyPeptide Group to convert its AI visibility into top-three recommendation placement?
• Is PolyPeptide Group's core problem reputation or recommendation conversion?

PolyPeptide Group's biggest opportunity is converting its rising presence into top-three recommendation placement within the Brand Recommendation cluster. The brand already appears in more than a quarter of qualified AI observations. The gap is not visibility but selection. AI systems are mentioning PolyPeptide Group without placing it in the recommended supplier shortlist.

The path forward is to strengthen the public evidence layer that AI systems retrieve when forming recommendations. The brand's positive sentiment profile suggests that when it is mentioned, the framing is favorable. The opportunity is to ensure that favorable framing translates into recommendation placement by making the brand's capabilities, manufacturing credentials, and supplier attributes more retrievable and more clearly associated with the prompts that drive supplier selection.

This is a recommendation-readiness problem, not a reputation problem. The brand does not need to overcome negative framing. It needs to convert neutral or contextual mentions into valid recommendations.

Competitive Landscape

Questions This Section Answers

• Where does PolyPeptide Group rank against competitors by top-three rate and rank-one rate?
• How does PolyPeptide Group's average recommended rank compare with Bachem and other rivals?

Bachem holds dominant recommendation power in Peptide API Manufacturing, with a top-three rate of 25.29% and a rank-one rate of 14.79% in September 2026. PolyPeptide Group sits in the middle of the tracked set by presence but near the bottom by recommendation placement, with a top-three rate of 1.95% and no rank-one recommendations.

Average recommended rank covers rank-eligible recommendations only.

PolyPeptide Group ranks fourth by top-three rate and holds no rank-one recommendations. Its average recommended rank of 3.4 places it behind Bachem, AmbioPharm, and Biosynth Peptide Division when it does receive rank credit. The table shows a brand with moderate presence and positive sentiment but limited recommendation conversion relative to the category leader and the strongest challengers.

Prompt Evidence

Questions This Section Answers

• Which prompts triggered a PolyPeptide Group recommendation—and which only produced a mention?
• What do the platform-level prompt results show about the gap between presence and shortlist placement?

Google AI Mode / Brand Recommendation Prompt: "What is the most reliable peptide company?" Result: PolyPeptide Group received a valid recommendation with a top-three placement, one of only three top-three recommendations the brand earned on this platform.

Gemini / Brand Recommendation Prompt: "Who is the most reputable peptide supplier?" Result: PolyPeptide Group appeared in the response but received no top-three recommendation, illustrating the gap between presence and shortlist placement on this platform.

Google AI Overviews / Brand Recommendation Prompt: "best peptide company" Result: PolyPeptide Group was mentioned in the response with positive framing but did not appear in the top-three recommended positions.

Copilot / Brand Recommendation Prompt: "bulk peptide supply" Result: PolyPeptide Group appeared in the response but received no top-three recommendation, consistent with its limited recommendation conversion on Copilot.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Map every prompt where PolyPeptide Group appears without a recommendation, identify which competitors occupy the top-three slots instead, and document the evidence sources AI systems retrieve for those prompts.

Phase 2: Recommendation Readiness Plan Prioritize the prompt clusters and platforms where the gap between presence and recommendation is widest, starting with Gemini and Copilot, and define the supplier attributes and proof points that need to be more retrievable.

Phase 3: Owned Answer Layer Buildout Strengthen the brand's owned pages so that capability, capacity, regulatory, and manufacturing credentials are clearly stated and easily extractable by AI systems forming supplier recommendations.

Phase 4: Citation / Authority Layer Development Build the public evidence layer that AI systems cite when recommending peptide API manufacturers, including industry directories, technical documentation, and third-party references that support recommendation placement.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track PolyPeptide Group's presence, valid recommendation coverage, top-three rate, and rank-one rate month over month to measure whether recommendation conversion improves as the evidence layer strengthens.

Why This Matters

AI systems are increasingly where buyer shortlists are formed. When a procurement team or CDMO selection committee asks an AI assistant for the most reliable peptide API manufacturer, the answer shapes which suppliers enter the evaluation set. PolyPeptide Group is appearing in those answers but is not being placed in the recommended shortlist at the rate its presence would suggest.

Presence alone is not enough. A brand can be mentioned in a quarter of AI responses and still be absent from the top-three recommendations that drive supplier consideration. The next move for PolyPeptide Group is targeted correction of the prompt, page, and citation layers that determine whether AI systems recommend the brand or merely reference it.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For PolyPeptide Group in September 2026: (62 × 1 + 5 × 0 + 0 × -1) / 67 = 0.9254.

This score matters because unclassified mention counts are misleading. A brand can appear frequently in AI responses without any of those appearances being positive, neutral, or negative in any meaningful sense. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal.

Counting all mentions as wins is bad measurement. PolyPeptide Group's 67 mentions include 62 positive and 5 neutral, with zero negative. That is a strong sentiment profile. But sentiment alone does not tell you whether the brand is being recommended. The brand's valid recommendation coverage of 5.84% is the metric that matters for shortlist eligibility. Classified sentiment is required before interpreting AI visibility, and it must be read alongside recommendation coverage, not instead of it.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of PolyPeptide Group's position in AI-generated recommendations for Peptide API Manufacturing, using the LLM Authority Index AI Market Discovery Index for September 2026.
2. The reporting window is September 2026, with comparison to July 2026 and August 2026 where the benchmark provides baseline data.
3. Six canonical AI/search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.
4. The September 2026 run collected 373 prompt-surface observations from 236 unique questions. Of these, 331 were relevant to the vertical and 42 were irrelevant, leaving 257 qualified observations as the public denominator for brand metrics.
5. The competitor universe consists of seven tracked brands: AmbioPharm, Bachem, Biosynth Peptide Division, CordenPharma Peptides, CPC Scientific, CSBio, and PolyPeptide Group.
6. All 257 qualified observations in September 2026 fell into the Brand Recommendation buyer-intent cluster. The Pricing and Value and Multi-Brand Comparison clusters contained zero qualified observations.
7. Stage 0 extraction retained the query, AI/search surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources.
8. A mention is counted when a brand appears in a qualified observation, regardless of whether it is recommended. Raw mention presence rate is the share of qualified observations in which the brand is mentioned at all.
9. A valid recommendation is counted when a brand receives a positive recommendation with a rank position of 1 through 10. Valid recommendation coverage is the share of qualified observations in which the brand receives a valid recommendation.
10. Top-three rate is the share of qualified observations in which the brand appears in the first three recommended positions. Rank-one rate is the share of qualified observations in which the brand is the first recommendation.
11. Average recommended rank covers rank-eligible recommendations only. A brand with no rank-eligible recommendations receives no average rank value.
12. Limitations: Several brands hold valid recommendation counts in single digits, including CSBio at 4, CordenPharma Peptides at 7, and CPC Scientific at 14. Percentage movement for these brands rests on a narrow base. The benchmark measures the Brand Recommendation class of discovery and does not yet contain qualified observations in the Pricing and Value or Multi-Brand Comparison classes. Source presence is evidence about the information environment and is not automatically proof that the source caused the recommendation.

See Where AI Is Recommending Your Brand

The public benchmark shows where PolyPeptide Group is winning and losing in AI-generated recommendations. A company-level AI visibility audit maps the specific prompts, platforms, competitors, and evidence sources that determine whether AI systems recommend your brand or merely mention it. Understanding which named supplier AI systems put first, and what evidence is associated with that outcome, is the foundation for protecting or improving position in AI-led supplier discovery.